Growth Metrics

Kiniksa Pharmaceuticals International (KNSA) Gains from Sales and Divestitures (2022 - 2025)

Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures history spans 4 years, with the latest figure at $771693.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures changed N/A year-over-year to $771693.0; the TTM value through Dec 2025 reached $771693.0, changed N/A, while the annual FY2025 figure was $771693.0, N/A changed from the prior year.
  • Gains from Sales and Divestitures reached $771693.0 in Q4 2025 per KNSA's latest filing, up from $698136.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $771693.0 in Q4 2025 to a low of $54349.0 in Q1 2025.
  • Average Gains from Sales and Divestitures over 4 years is $320513.6, with a median of $261365.0 recorded in 2022.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 103.31% in 2023, then crashed 52.54% in 2024.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $250805.0 in 2022, then soared by 85.76% to $465891.0 in 2023, then grew by 29.59% to $603762.0 in 2024, then increased by 27.81% to $771693.0 in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Gains from Sales and Divestitures are $771693.0 (Q4 2025), $698136.0 (Q3 2025), and $342204.0 (Q2 2025).